Studies on Chemically Modified Fibrinogen

Summary

Treatment of fibrinogen with maleic acid anhydride renders fibrinogen unclottable depending on the degree of modification of the molecule. According to radioactive studies the release of fibrinopeptides by thrombin or reptilase is undisturbed. The incoagulability is due to inhibition of the polymerization process of fibrinmonomers derived from modified fibrinogen, mainly caused by the increase of electronegative charges upon the fibrinogen molecule. According to discelectrophoretic analysis modified fibrinogen fails to produce fragments D and E following plasmic digestion, however, may be degraded to high molecular weight products. Modified fibrinogen reveals some similarities to abnormal fibrinogens in congenital dysfibrinogenemia with regard to its functional properties.

• References

• 1 Beck E. A, Mosesson M. W, Charache P, Jackson P. D. 1966; Hämorrhagische Diathese mit dominantem Erbgang, verursacht durch ein anomales Fibrinogen (Fibrinogen Baltimore). Schweizerische medizinische Wochenschrift 96: 1196.
• 2 Bray G. A. 1960; A simple efficient liquid scintillator for counting aequeous solutions in a liquid scintillation counter. Analytical Biochemistry 1: 279.
• 3 Budzynski A. Z, Stahl M, Kopec, Latallo Z. S, Wegrzynowicz Z. 1967; High molecular weight products of the late stage of fibrinogen proteolysis by plasmin and their structural relations to the fibrinogen molecule. Biochemica et Biophysicas. Acta 147: 313.
• 4 Butler P. J. G, Hartley B. S. 1972. Maleylation of amino groups. In: Colowick S. P, Kaplan N. O. (Eds.) Methods in Enzymology 25,. B, 191 Academic Press; New York, London:
• 5 Crum E. D, Shainoff J. R, Graham R. C, Ratnoff O. D. 1974; Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A. Journal of Clinical Investigations 53: 1308.
• 6 Felten, von A. F, Duckert F, Frick P. 1965; Gerinnungsstörung ohne hämorrhagische Diathese infolge verzögerter Aggregation der Fibrinmoleküle. Schweizerische medizinische Wochenschrift 95: 1453.
• 7 Funck C, Straub P. W. 1970; Hereditary abnormality of fibrin monomer aggregation (Fibrinogen Zürich II). European Journal of Clinical Investigation 1: 131.
• 8 Gralnick H. R, Girelber H. M, Finlayson J. S. 1970; A familial bleeding disorder associated with dysfibrinogenemia (Fibrinogen “Bethesda”). Clinical Research 18: 405.
• 9 Gralnick H. R, Girelber H. M, Finlayson J. S. 1973; Anew congenital abnormality of human fibrinogen (Fibrinogen Bethesda II). Thrombosis et Diathesis Haemorrhagica 29: 652.
• 10 Habeeb A. F. S. A. 1966; Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Analytical Biochemistry 14: 328.
• 11 Janssen C. L, Vreeken J. 1971; Fibrinogen Amsterdam: another hereditary abnormality of fibrinogen. British Journal of Haematology 20: 287.
• 12 Keckwick R. A, Mackay M. E, Nance M. H, Record B. R. 1955; The purification of human fibrinogen. Biochemical Journal 60: 671.
• 13 Kloczewiak M. et al. in preparation.
• 14 Krause W. H, Heene D. L, Lasch H. G. 1973; Congenital dysfibrinogenemia (Fibrinogen Gießen). Thrombosis et Diathesis Haemorrhagica 26: 547.
• 15 Krause W. H, Bleyl H. 1973; Investigation on plasmin-proteolysis of abnormal fibrinogen (Fibrinogen Gießen). Thrombosis Research 2: 361.
• 16 Lacombe M, Soria J, Soria C, D’Angelo G, Lavellee R, Bonny Y. 1973; Fibrinogen Montreal. A new case of congenital dysfibrinogenemia with defective aggregation of monomers. Thrombosis et Diathesis Haemorrhagica 29: 536.
• 17 Martinez J, Holburn R. R, Shapiro S. S, Erslev A. J. 1974; Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism. Journal of Clinical Investigation 53: 600.
• 18 Menaché D. 1973; Abnormal fibrinogens. A review. Thrombosis et Diathesis Haemorrhagica 29: 525.
• 19 Menaché D. 1963; Dysfibrinogenemie constitutionelle et familiale. Proceedings of the IXth Congress of the European Society of Haematology, II 2: 1255.
• 20 Mosesson M. W, Beck E. A. 1969; Chromatographic, ultracentrifugal and related studies of fibrinogen “Baltimore”. Journal of Clinical Investigation 48: 1656.
• 21 Samama M, Soria J, Soria C, Bousser J. 1969; Dysfibrinogènèmié congenitale et familiale sans tendance hèmorrhagique. Nov. Rev. Franc. D’Hèmatol 9: 817.
• 22 Schachman H. K. 1959. Ultracentrifugation in Biochemistry. Academic Press. Inc.; New York: p. 75.
• 23 Soria J, Soria C, Samama M, Poirot E, Kling C. 1972; Fibrinogen “Troyes”, fibrinogen “Metz”. Two new cases of congenital dysfibrinogenemia. Thrombosis et Diathesis Haemorrhagica 27: 619.
• 24 Streiff F, Alexandre P, Vigeron C, Soria J, Soria C, Mester L. 1971; Un nouveau cas d’anomalie constitutionelle et familiale du fibrinogène sans diathèse hémorragique. Thrombosis et Diathesis Haemorrhagica 26: 565.
• 25 Swank R. T, Munkres K. D. 1971; Molecular weight analysis of ologopeptides by electrophoresis in Polyacrylamide gel with sodium-dodecyl-sulfate. Analytical Biochemistry 39: 462.
• 26 Verhaeghe R, Verstraete M, Vermylen J, Vermylen C. 1974; Fibrinogen ‘Leuven’, another genetic variant. British Journal of Haematology 26: 241.
• 27 Witt J, Hasler K, Karitzky D. 1973; Nachweis von fetalem Fibrinogen in Neugeborenen-Plasma. Klinische Wochenschrift 51: 703.
• 28 Zietz B. H, Scott J. L. 1970; An inherited defect in fibrinogen polymerization: fibrinogen “Los Angeles”. Clinical Research 18: 179.